1. Clinical & Scientific Overview
Torsemide (Torasemide) (TIP-MED-000014, Reference Code [3.14]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Loop Diuretic (Pyridine-Sulfonylurea Derivative with Mild Anti-Aldosterone Property).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.14], p. 27): Dytor (Cipla), Tide (Torrent), Torsid (Intas); Combined with Spironolactone: Dytor Plus (Cipla), Tide Plus (Torrent) — Strengths & Dosage Forms: Oral Uncoated Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 100 mg; Injection: 10 mg/mL
Oral Uncoated Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 100 mg; Injection: 10 mg/mL
3. Mechanism of Action & Pharmacodynamics
Loop Diuretic (Pyridine-Sulfonylurea Derivative with Mild Anti-Aldosterone Property) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Loop Diuretic (Pyridine-Sulfonylurea Derivative with Mild Anti-Aldosterone Property) for Oedema associated with congestive heart failure, chronic kidney disease, and hepatic cirrhosis; essential hypertension..
4. Therapeutic Indications & Evidence-Supported Uses
- Oedema associated with congestive heart failure, chronic kidney disease, and hepatic cirrhosis
- essential hypertension
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Heart Failure / Renal Oedema: Initially 10 mg–20 mg once daily (10 mg torsemide is approximately equipotent to 20–40 mg oral furosemide). Hypertension: 2.5 mg–5 mg once daily. Follow physician prescription.
Administration & Meal Timing: With or without food (unlike furosemide, oral bioavailability is consistently 80–90% regardless of food intake). | Standard OPD schedule: Once daily in the morning (08:00–09:00 AM) to prevent nocturia; in severe heart failure or resistant oedema, follow specialist split/timed regimen.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Cleared 80% via hepatic CYP2C9 metabolism and only 20% unchanged in urine—therefore, half-life does not prolong significantly in CKD, while natriuretic efficacy is maintained in advanced renal failure. Hepatic: Elimination half-life doubles in cirrhosis; titrate cautiously with spironolactone.
Renal: Cleared 80% via hepatic CYP2C9 metabolism and only 20% unchanged in urine—therefore, half-life does not prolong significantly in CKD, while natriuretic efficacy is maintained in advanced renal failure. Hepatic: Elimination half-life doubles in cirrhosis; titrate cautiously with spironolactone.
Renal: Cleared 80% via hepatic CYP2C9 metabolism and only 20% unchanged in urine—therefore, half-life does not prolong significantly in CKD, while natriuretic efficacy is maintained in advanced renal failure. Hepatic: Elimination half-life doubles in cirrhosis; titrate cautiously with spironolactone.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in anuria, hepatic coma, severe electrolyte depletion, and sulfonylurea hypersensitivity. Caution in BPH and gout.
Key Clinical Precautions: Renal: Cleared 80% via hepatic CYP2C9 metabolism and only 20% unchanged in urine—therefore, half-life does not prolong significantly in CKD, while natriuretic efficacy is maintained in advanced renal failure. Hepatic: Elimination half-life doubles in cirrhosis; titrate cautiously with spironolactone.
8. Adverse Effects Profile
- Increased urination (longer, smoother duration than furosemide), postural dizziness, mild hypokalaemia (less pronounced than furosemide due to weak aldosterone antagonism), hyperuricaemia, muscle cramps.
- Extracellular volume depletion, prerenal azotaemia, severe hyponatraemia/hypokalaemia, ototoxicity (at high parenteral doses).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- NSAIDs blunt diuretic efficacy and increase AKI risk
- Digoxin (monitor K+)
- Lithium (reduced renal clearance)
- Probenecid reduces tubular secretion of torsemide
- Cholestyramine reduces absorption
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Explain that torsemide has much more predictable absorption than furosemide, even when stomach wall swelling is present in heart failure, and causes slightly less potassium loss. Take every morning and track daily weight.
- Meal & Clock Timing Instruction: With or without food (unlike furosemide, oral bioavailability is consistently 80–90% regardless of food intake). (Standard OPD schedule: Once daily in the morning (08:00–09:00 AM) to prevent nocturia; in severe heart failure or resistant oedema, follow specialist split/timed regimen.)
- Missed Dose Protocol: Take if remembered before 02:00–03:00 PM; skip if remembered later in the afternoon/evening.
- Geriatric Dispensing Pearl: Often preferred over furosemide in elderly HFrEF patients because of reliable 80–90% bioavailability, once-daily convenience, and less abrupt urinary urgency.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Tablets: 5 mg, 10 mg, 20 mg, 40 mg, 100 mg; Injection: 10 mg/mL
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.14] (p. 27)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.16] Atorvastatin Calcium — HMG-CoA Reductase Inhibitor (Lipophilic Statin); Lipid-Lowering &
- [3.17] Rosuvastatin Calcium — HMG-CoA Reductase Inhibitor (Hydrophilic, High-Potency Statin)
- [3.18] Aspirin (Acetylsalicylic Acid — Low-Dose Antiplatelet) — Irreversible Cyclooxygenase-1 (COX-1) Inhibitor; Thromboxane A2 S
- [3.19] Clopidogrel Bisulfate — Thienopyridine P2Y12 ADP-Receptor Antagonist (Prodrug Antiplatele
